Dystrophic Epidermolysis Bullosa Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, NICE Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, USA) "Dystrophic Epidermolysis Bullosa Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dystrophic Epidermolysis Bullosa Market.
Dystrophic Epidermolysis Bullosa pipeline constitutes 15+ key companies continuously working towards developing 15+ Dystrophic Epidermolysis Bullosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Dystrophic Epidermolysis Bullosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report:
• Dystrophic Epidermolysis Bullosa Companies across the globe are diligently working toward developing novel Dystrophic Epidermolysis Bullosa treatment therapies with a considerable amount of success over the years. Dystrophic Epidermolysis Bullosa companies working in the treatment market are Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others, are developing therapies for the Dystrophic Epidermolysis Bullosa treatment
• Dystrophic Epidermolysis Bullosa Emerging therapies such as - VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others are expected to have a significant impact on the Dystrophic Epidermolysis Bullosa market in the coming years.
• In April 2025, Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYNTM (pronounced as 'ZEE-vah-skin') (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel, as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. There is no cure for RDEB and ZEVASKYN is the only FDA-approved product to treat RDEB wounds with a single application.
• In February 2025, INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.
• In November 2024, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy being evaluated as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB).

Dystrophic Epidermolysis Bullosa Overview
Dystrophic Epidermolysis Bullosa (DEB) is a rare, inherited skin disorder characterized by extreme skin fragility, leading to blistering and skin erosion from minor friction or trauma. Dystrophic Epidermolysis Bullosa symptoms often manifest at birth or in early childhood and include painful blisters, scarring, nail loss, and mucosal involvement affecting the eyes, mouth, and esophagus. Dystrophic Epidermolysis Bullosa causes are primarily linked to mutations in the COL7A1 gene, which encodes type VII collagen-crucial for anchoring fibrils that bind the dermis and epidermis. Dystrophic Epidermolysis Bullosa diagnosis involves clinical evaluation, genetic testing, and immunofluorescence mapping to confirm the subtype and severity.

Dystrophic Epidermolysis Bullosa treatment is currently symptomatic, focusing on wound care, infection prevention, nutritional support, and pain management. Advanced therapeutic approaches, including gene therapy and protein replacement, are under investigation. Dystrophic Epidermolysis Bullosa prognosis varies by subtype-recessive forms tend to be more severe with potential complications like skin cancer and contractures. Dystrophic Epidermolysis Bullosa research is advancing with clinical trials exploring targeted molecular treatments to improve quality of life and survival. Dystrophic Epidermolysis Bullosa awareness and early intervention play a crucial role in improving patient outcomes. Overall, Dystrophic Epidermolysis Bullosa represents a significant area of unmet medical need, drawing increased attention from researchers, clinicians, and pharmaceutical developers.

Get a Free Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa Pipeline Assessment-
https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Dystrophic Epidermolysis Bullosa Drugs Under Different Phases of Clinical Development Include:
• VYJUVEK (beremagene geperpavec): Krystal Biotech
• FILSUVEZ (birch triterpenes): Chiesi
• PTW-002 10 mg/g gel: Phoenicis Therapeutics
• AGLE 102: Aegle Therapeutics
• ALLO-ASC-SHEET: Anterogen Co., Ltd.
• EB-101: Abeona Therapeutics, Inc
• FCX-007: Castle Creek Bioscience
• PTR-01: Phoenix Tissue Repair, Inc.
• SD-101-6.0 cream: Scioderm, Inc.
• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Dystrophic Epidermolysis Bullosa Pipeline Therapeutics Assessment
• Dystrophic Epidermolysis Bullosa Assessment by Product Type
• Dystrophic Epidermolysis Bullosa By Stage and Product Type
• Dystrophic Epidermolysis Bullosa Assessment by Route of Administration
• Dystrophic Epidermolysis Bullosa By Stage and Route of Administration
• Dystrophic Epidermolysis Bullosa Assessment by Molecule Type
• Dystrophic Epidermolysis Bullosa by Stage and Molecule Type

DelveInsight's Dystrophic Epidermolysis Bullosa Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download Sample PDF Report to know more about Dystrophic Epidermolysis Bullosa drugs and therapies-
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dystrophic Epidermolysis Bullosa Pipeline Analysis:
The Dystrophic Epidermolysis Bullosa pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Dystrophic Epidermolysis Bullosa treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
• Dystrophic Epidermolysis Bullosa key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Dystrophic Epidermolysis Bullosa product details are provided in the report. Download the Dystrophic Epidermolysis Bullosa pipeline report to learn more about the emerging Dystrophic Epidermolysis Bullosa therapies at:
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Dystrophic Epidermolysis Bullosa Pipeline Market Drivers
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs

Dystrophic Epidermolysis Bullosa Pipeline Market Barriers
• Currently no cure for all types of dystrophic epidermolysis bullosa (DEB)
• Making a diagnosis for a genetic or rare disease is often challenging

Scope of Dystrophic Epidermolysis Bullosa Pipeline Drug Insight
• Coverage: Global
• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech (NASDAQ: KRYS), Chiesi Farmaceutici (Private), Phoenicis Therapeutics (Private), Aegle Therapeutics (Private), Anterogen Co., Ltd. (KOSDAQ: 065660), Abeona Therapeutics, Inc. (NASDAQ: ABEO), Castle Creek Biosciences (Private), Phoenix Tissue Repair, Inc. (Private), Scioderm, Inc. (Acquired by Amicus Therapeutics - NASDAQ: FOLD), InMed Pharmaceuticals Inc. (NASDAQ: INM), and others.
• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers

Request for Sample PDF Report for Dystrophic Epidermolysis Bullosa Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1 Dystrophic Epidermolysis Bullosa Report Introduction
2 Dystrophic Epidermolysis Bullosa Executive Summary
3 Dystrophic Epidermolysis Bullosa Overview
4 Dystrophic Epidermolysis Bullosa- Analytical Perspective In-depth Commercial Assessment
5 Dystrophic Epidermolysis Bullosa Pipeline Therapeutics
6 Dystrophic Epidermolysis Bullosa Late Stage Products (Phase II/III)
7 Dystrophic Epidermolysis Bullosa Mid Stage Products (Phase II)
8 Dystrophic Epidermolysis Bullosa Early Stage Products (Phase I)
9 Dystrophic Epidermolysis Bullosa Preclinical Stage Products
10 Dystrophic Epidermolysis Bullosa Therapeutics Assessment
11 Dystrophic Epidermolysis Bullosa Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Dystrophic Epidermolysis Bullosa Key Companies
14 Dystrophic Epidermolysis Bullosa Key Products
15 Dystrophic Epidermolysis Bullosa Unmet Needs
16 Dystrophic Epidermolysis Bullosa Market Drivers and Barriers
17 Dystrophic Epidermolysis Bullosa Future Perspectives and Conclusion
18 Dystrophic Epidermolysis Bullosa Analyst Views
19 Appendix
20 About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.